Efficacy and Safety of COVID-19 Vaccines in Children

Standout updates include a relaxed recommendation for patients with a history of egg allergies, and that all available influenza vaccines for the 2023 to 2023 flu season are quadrivalent.

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

According to a recent Morbidity and Mortality Weekly Report, the original COVID-19 monovalent and bivalent vaccines helped reduce emergency department or urgent care encounters for children aged 6 months to 5 years.

Contemporary Pediatrics sat down with Dr. Donna Hallas to discuss how to communicate with parents as well as how to address vaccines missed because of the pandemic.

Ervebo has been approved by the FDA to prevent the Ebola virus for individuals aged 12 months and older, after being initially approved for those 18 years and older in 2019.

In unanimous fashion, the FDA AMDAC voted 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.